Volume : 11, Issue : 02, February – 2024
Title:
A CONCEPT ON SOURCES OF IMPURITIES
Authors :
T. Rupa Devi, B. Akhila
Abstract :
The impurities in pharmaceuticals are unwanted chemicals that remain with the active pharmaceutical ingredients (APIs) or develop during formulation or upon ageing of both API and formulation. The presence of these unwanted chemicals even in trace amounts may influence the efficacy and safety of pharmaceutical products. The control of impurities is currently a critical issue to the pharmaceutical industry. The International Conference on Harmonization (ICH) formulated guidelines regarding the control of impurities. This review outlines the description of different types and origins of impurities and degradation routes with specific examples.
Keywords: Impurities, formulation, efficacy, degradation.
Cite This Article:
Please cite this article in press T. Rupa Devi et al., A Concept On Sources Of Impurities, 2024; 11 (02).
Number of Downloads : 10
References:
1. Chatwal. G.R, Pharmaceutical Chemistry – Organic Volume -2, 2006, Reader in Chemistry, Dyal Singh College, University of Delhi -110003.
2. huja S., Impurities Evaluation of Pharmaceuticals. Marcel Dekker, New York, 1998, 142.
3. Riley T N. Steric aspects of drug action. Pharmacist 1998; 23(3): 40.
4. International Conference on Harmonization (1997) Impurities, Q3CGuidelines for Residual Solvents, Q3C. Federal Register 62(247): 67377.
5. Jacobs P, Dewe W, Flament A, Gibella M, Ceccato A. A new validation approach applied to the GC determination of impurities in organic solvents. J Pharm Biomed Anal 2005; 40:294-304.
6. Jack Yuk K Cheng, Man Fai Chan, Tai Wai Chan, Mei Yuen Hung. Impurity profiling of ecstasy tablets seized in Hong Kong by GC-MS. Forensic Science International 2006; 144:21.
7. Gimeno P, Besacier F, Bottex M, Dujourdy L, Chaudron-Thozet H. A study impurities in intermediates and 3 methylenedioxymethamphetamine (MDMA) samples produced via reductive amination routes. Forensic Science International 2005; 155:141-157.
8. Buhler V. Vademecum for Vitamin Formulation. Stuttgart, Germany, Wiss, Verl-Ges., 1998; 142:36.
9. Food and Drug Administration for Immediate Release Consumer Media.
10. VasantiS, SulabhaS. Impurity profile-Areview. Drug invention today 2009; 1(2), 81-88.
11. Gazdag M, Babjag M, Brlik J, Maho S, Tuba Z and Gorog S et al. Estimation of profile of drug and related materials Part 18. Impurities and degradation product of mazipredone. J Pharm Biomed Anal 1998; 17:1029.
12. Roy J, Bhuiyan K, Faraque A, Sobahan M, Al-Farooque M. Injectable ergometrine: stability and packaging for developing countries, Indian Drugs 1997; 34(11): 634-636.
13. Kumar V, Sunder N and Potdar A. Critical factors in developing pharmaceutical formulations-An overview Part II. Pharma Tech1992; 16:86-88.
14. Smith A, Pennefather P M, Kaye S B and Hart C A. Fluroquinolonesplace in ocular therapy. Indian Drugs 2001;61(6): 747-76